Anti-VEGF therapy in proliferative diabetic retinopathy

International Ophthalmology Clinics

Volumn 49, Issue 2, 2009, Pages 95-107

  Abdallah, Walid ^a   Fawzi, Amani A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; APTAMER; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ARTERY THROMBOSIS; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG ACTIVITY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; ENDOPHTHALMITIS; HEART INFARCTION; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INTESTINE PERFORATION; NONHUMAN; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA TEAR; REVIEW; STROKE; TRAUMATIC CATARACT; VISUAL HALLUCINATION; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; INJECTION; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; VITREORETINOPATHY; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 67650242714     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/IIO.0b013e31819fd84a     Document Type: Review

References (86)

1. Varma R, Torres M, Pena F, et al. Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino eye study. Ophthalmology. 2004;111:1298-1306. (Pubitemid 38844824)
2. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552-563. (Pubitemid 38456292)
3. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology. 1981;88:583-600.
4. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98(5 suppl):766-785.
5. Flynn HW Jr, Chew EY, Simons BD, et al. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1992;99:1351-1357.
6. Aaberg TM, Abrams GW. Changing indications and techniques for vitrectomy in management of complications of diabetic retinopathy. Ophthalmology. 1987;94:775-779.
7. Sima P, Zoran T. Long-term results of vitreous surgery for proliferative diabetic retinopathy. Doc Ophthalmol. 1994;87:223-232. (Pubitemid 24326967)
8. Karel I, Kalvodova B. Long-term results of pars plana vitrectomy and silicone oil for complications of diabetic retinopathy. Eur J Ophthalmol. 1994;4:52-58. (Pubitemid 24110397)
9. Schachat AP, Oyakawa RT, Michels RG, et al. Complications of vitreous surgery for diabetic retinopathy. II. Postoperative complications. Ophthalmology. 1983;90:522-530.
10. Aanderud S, Krane H, Nordoy A. Influence of glucose, insulin and sera from diabetic patients on the prostacyclin synthesis in vitro in cultured human endothelial cells. Diabetologia. 1985;28:641-644. (Pubitemid 16226399)
11. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007;3:853-876.
12. Kohner EM, Hamilton AM, Saunders SJ, et al. The retinal blood flow in diabetes. Diabetologia. 1975;11:27-33.
13. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
14. Michaelson IC. The mode of development the vascular system of the retina with some observation on its significance for certain retinal disorders. Trans Ophthalmol Soc UK. 1948;68:137-180.
15. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145:574-584. (Pubitemid 24285965)
16. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
17. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395.
18. Simo R, Carrasco E, Garcia-Ramirez M, et al. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2:71-98. (Pubitemid 44082952)
19. Veeravagu A, Hsu AR, Cai W, et al. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Pat Anticancer Drug Discov. 2007;2:59-71. (Pubitemid 46723152)
20. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103:1820-1828.
21. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66-71. (Pubitemid 26026196)
22. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450. (Pubitemid 24307211)
23. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs. 2008;68:1029-1036. (Pubitemid 351693673)
24. Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 2006;13:225-234. (Pubitemid 43148645)
25. Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res. 2000;17:1503-1510. (Pubitemid 32217559)
26. Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002;160:501-509. (Pubitemid 34160327)
27. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci. 2003;44:2155-2162.
28. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003;198:483-489. (Pubitemid 36976059)
29. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18:3964-3972. (Pubitemid 29335849)
30. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747-1757.
31. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816. (Pubitemid 40051904)
32. D'Amico DJ, Masonson HN, Patel M, et al; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006;113:992-1001. e6.
33. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology. 2006;113:23-28. (Pubitemid 43021723)
34. Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48:257-293. (Pubitemid 36553096)
35. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726-733. (Pubitemid 40270359)
36. Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:623.e1.
37. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007;27:1260-1266. (Pubitemid 350211535)
38. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239-248.
39. Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 2007;125:1460-1469. (Pubitemid 350106676)
40. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444. (Pubitemid 44511558)
41. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431. (Pubitemid 44511557)
42. Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006;113:1706-1712.
43. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142:961-969. (Pubitemid 44853891)
44. Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema. 2008. Available at: http://public.drcr.net/DRCRnetstudies/StudiesIndex.html. Accessed: November 10, 2008.
45. Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy. 2008. Available at: http://public.drcr.net/DRCRnetstudies/StudiesIndex.html. Accessed: November 10, 2008.
46. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400. (Pubitemid 38618122)
47. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695, e1-15. (Pubitemid 44442453)
48. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
49. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855-859.
50. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26:279-284. (Pubitemid 44318180)
51. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336-339. (Pubitemid 41073113)
52. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511. (Pubitemid 44620390)
53. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335. (Pubitemid 41073112)
54. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275-278. (Pubitemid 44318179)
55. Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg. 2006;63:334-337. (Pubitemid 44340939)
56. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232-1239.
57. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-1349. (Pubitemid 44702055)
58. Meyer CH, Mennel S, Horle S, et al. Visual hallucinations after intravitreal injection of bevacizumab in vascular age-related macular degeneration. Am J Ophthalmol. 2007;143:169-170. (Pubitemid 44917816)
59. Menon GJ, Rahman I, Menon SJ, et al. Complex visual hallucinations in the visually impaired: the Charles Bonnet Syndrome. Surv Ophthalmol. 2003;48:58-72. (Pubitemid 36136084)
60. Cohen SY, Safran AB, Tadayoni R, et al. Visual hallucinations immediately after macular photocoagulation. Am J Ophthalmol. 2000;129:815-816. (Pubitemid 30604171)
61. Herrero-Vanrell R, Refojo MF. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Deliv Rev. 2001;52:5-16. (Pubitemid 32973634)
62. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003;136:791-796. (Pubitemid 37330020)
63. Yuen HK, Chan CK, Lam D. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2004;137:1166; author reply 7.
64. Canakis C, Livir-Rallatos C, Zafirakis P, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2004;137:1158-1159; author reply 1160-1161. (Pubitemid 38759384)
65. Jager RD, Aiello LP, Patel SC, et al. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24:676-698.
66. Jonas JB, Spandau UH, Rensch F, et al. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther. 2007;23:240-242. (Pubitemid 46986604)
67. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92:213-216. (Pubitemid 351224097)
68. Arevalo JF, Wu L, Sanchez JG, et al. Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6- months follow-up. Eye. 2009;23:117-123.
69. Tonello M, Costa RA, Almeida FP, et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol. 2008;86:385-389.
70. Mirshahi A, Roohipoor R, Lashay A, et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol. 2008;18:263-269. (Pubitemid 351692187)
71. Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina. 2006;26:1006-1013. (Pubitemid 44973219)
72. Moradian S, Ahmadieh H, Malihi M, et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246:1699-1705.
73. Beutel J, Peters S, Lüke M, et al, the Bevacizumab Study Group. Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol. 2008 Sep 20. [Epub ahead of print].
74. Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther. 2008;25:438-443.
75. Miki A, Oshima Y, Otori Y, et al. Efficacy of intravitreal bevacizumab as adjunctive treatment with pars plana vitrectomy, endolaser photocoagulation, and trabeculectomy for neovascular glaucoma. Br J Ophthalmol. 2008;92:1431-1433.
76. Ishikawa K, Honda S, Tsukahara Y, et al. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye. 2009;23:108-111.
77. Yeoh J, Williams C, Allen P, et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol. 2008;36:449-454.
78. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006;26:699-700. (Pubitemid 44620378)
79. Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008;246:837-842.
80. Yang CM. Surgical treatment for diabetic retinopathy: 5-year experience. J Formos Med Assoc. 1998;97:477-484. (Pubitemid 28378396)
81. West JF, Gregor ZJ. Fibrovascular ingrowth and recurrent haemorrhage following diabetic vitrectomy. Br J Ophthalmol. 2000;84:822-825.
82. Novak MA, Rice TA, Michels RG, et al. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology. 1984;91:1485-1489. (Pubitemid 15197020)
83. Yang CM, Yeh PT, Yang CH, et al. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol. 2008;146:211-217.
84. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195:241-248. (Pubitemid 36384298)
85. Tremolada G, Lattanzio R, Mazzolari G, et al. The therapeutic potential of VEGF inhibition in diabetic microvascular complications. Am J Cardiovasc Drugs. 2007;7:393-398. (Pubitemid 350256047)
86. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-1625. (Pubitemid 40770750)